相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
A. Szarewski et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Male vaccination against human papillomavirus
David M. Salisbury
LANCET INFECTIOUS DISEASES (2012)
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Matti Lehtinen et al.
LANCET ONCOLOGY (2012)
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Cosette M. Wheeler et al.
LANCET ONCOLOGY (2012)
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
X. Castellsague et al.
BRITISH JOURNAL OF CANCER (2011)
Until Which Age Should Women Be Vaccinated Against HPV Infection? Recommendation Based on Cost-effectiveness Analyses
Tjalke A. Westra et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine
Aimee R. Kreimer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands
Johannes A. Bogaards et al.
VACCINE (2011)
Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model
Mark Jit et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom
Yoon Hong Choi et al.
VACCINE (2010)
Determinants for HPV vaccine uptake in the Netherlands: A multilevel study
Marc Rondy et al.
VACCINE (2010)
Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States
Jane J. Kim et al.
ANNALS OF INTERNAL MEDICINE (2009)
The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey
D. Levy-Bruhl et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Age-Based Programs for Vaccination against HPV
Elamin H. Elbasha et al.
VALUE IN HEALTH (2009)
Health and economic implications of HPV vaccination in the United States
Jane J. Kim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model
Cara Usher et al.
VACCINE (2008)
Economic evaluation of human papillomavirus vaccination in the United Kingdom
Mark Jit et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: A transmission dynamic model-based evaluation
Ralph P. Insinga et al.
VACCINE (2007)
Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection - A randomized trial
Allan Hildesheim et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial
H. C. Kitchener et al.
BRITISH JOURNAL OF CANCER (2006)
The global health burden of infection -associated cancers in the year 2002
Donald Maxwell Parkin
INTERNATIONAL JOURNAL OF CANCER (2006)
Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK
R. E. Brown et al.
CURRENT MEDICAL RESEARCH AND OPINION (2006)
Costs of running a universal adolescent hepatitis B vaccination programme
LA Wallace et al.
VACCINE (2005)
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
SJ Goldie et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Against which human papillomavirus types shall we vaccinate and screen?: The international perspective
N Muñoz et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
分享论文
